The laboratory of José Luis Hernández at the Biomed division, LEITAT Technology Center of Barcelona works in the clinical application of two antibodies designed by them to block proliferative function of extracellular S100 proteins.

Hernandez explained his research on April 26 at a conference framed at IDIBELL seminars cycle.

“We designed two antibodies that block at S100 extracellular proteins” explained Hernandez “and we observed in vivo and in vitro that slows tumor growth and metastasis in various cancers.” As explained by the researcher, today, “we are in process of humanizing antibodies and to seek funding to test results in patients.” Antibodies also have been useful in diagnosis. “We have seen in colon cancer patients at Hospital del Mar that high levels of S100 proteins in blood and other fluids are markers of poor prognosis.”